Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania

Olivia F Hunter1,2, Furaha Kyesi3, Amrit Kaur Ahluwalia4

  • 1Dartmouth College, Hanover, NH, 03755, USA. olivia.frances.hunter@gmail.com.

BMC Infectious Diseases
|October 8, 2020
PubMed

Insights

Isoniazid preventive therapy (IPT) for children living with HIV in Tanzania showed high adherence and completion rates when integrated into routine care. This study demonstrates IPT is feasible and well-tolerated in this population.

Area of Science:

  • Pediatric infectious diseases
  • Public health interventions
  • HIV/AIDS management

Background:

  • Tuberculosis (TB) prevention guidelines recommend isoniazid preventive therapy (IPT) for children aged 12 months and older living with HIV.
  • Global uptake of IPT in children is limited by concerns regarding tolerability, adherence, and potential mistreatment of undiagnosed TB.
  • Diagnostic confirmation of TB in children presents significant challenges.

Purpose of the Study:

  • To assess the implementation and adherence of isoniazid preventive therapy (IPT) in a pediatric HIV clinic in Tanzania.
  • To evaluate the feasibility and tolerability of a 6-month daily isoniazid regimen for children living with HIV.
  • To determine treatment completion rates and adherence levels for IPT in this vulnerable population.

Main Methods:

  • Prospective cohort study involving 66 children aged 1-15 years living with HIV who screened negative for TB disease.
  • Offered a 6-month daily isoniazid regimen, with options for facility- or community-based care.
  • Adherence and completion determined by pill counts, appointment attendance, and self-report; TB symptom screening at all visits.

Main Results:

  • No participants declined IPT; 74.2% completed the 6-month regimen within 10 months.
  • High average monthly adherence of 98.0% among completers.
  • IPT was well-tolerated, with only 11 participants discontinuing due to adverse drug reactions; no TB cases were detected during or after IPT.

Conclusions:

  • High adherence and treatment completion rates are achievable when IPT is integrated into routine, facility-based pediatric HIV care.
  • IPT is well-tolerated and effective in preventing TB in children living with HIV.
  • IPT implementation is feasible in Tanzania and should be widely adopted for pediatric HIV care.
Abstract

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
355
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
311
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
130
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
579
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.0K
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
677